186 related articles for article (PubMed ID: 17290408)
1. Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules.
Bluman EM; Coulie PG; Xiaojuan S; Machan J; Lin C; Meitner PA; Block JA; Terek RM
J Orthop Res; 2007 May; 25(5):678-84. PubMed ID: 17290408
[TBL] [Abstract][Full Text] [Related]
2. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
[TBL] [Abstract][Full Text] [Related]
3. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
Schultz ES; Lethé B; Cambiaso CL; Van Snick J; Chaux P; Corthals J; Heirman C; Thielemans K; Boon T; van der Bruggen P
Cancer Res; 2000 Nov; 60(22):6272-5. PubMed ID: 11103782
[TBL] [Abstract][Full Text] [Related]
4. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
Kobayashi H; Song Y; Hoon DS; Appella E; Celis E
Cancer Res; 2001 Jun; 61(12):4773-8. PubMed ID: 11406551
[TBL] [Abstract][Full Text] [Related]
5. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
6. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307
[TBL] [Abstract][Full Text] [Related]
7. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte.
Lethé B; van der Bruggen P; Brasseur F; Boon T
Melanoma Res; 1997 Aug; 7 Suppl 2():S83-8. PubMed ID: 9578421
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus targeting to HLA-A1/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX.
de Vrij J; Uil TG; van den Hengel SK; Cramer SJ; Koppers-Lalic D; Verweij MC; Wiertz EJ; Vellinga J; Willemsen RA; Hoeben RC
Gene Ther; 2008 Jul; 15(13):978-89. PubMed ID: 18323790
[TBL] [Abstract][Full Text] [Related]
9. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
[TBL] [Abstract][Full Text] [Related]
10. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.
Connerotte T; Van Pel A; Godelaine D; Tartour E; Schuler-Thurner B; Lucas S; Thielemans K; Schuler G; Coulie PG
Cancer Res; 2008 May; 68(10):3931-40. PubMed ID: 18483279
[TBL] [Abstract][Full Text] [Related]
11. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
[TBL] [Abstract][Full Text] [Related]
12. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry.
Pascolo S; Schirle M; Gückel B; Dumrese T; Stumm S; Kayser S; Moris A; Wallwiener D; Rammensee HG; Stevanovic S
Cancer Res; 2001 May; 61(10):4072-7. PubMed ID: 11358828
[TBL] [Abstract][Full Text] [Related]
13. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.
So T; Hanagiri T; Chapiro J; Colau D; Brasseur F; Yasumoto K; Boon T; Coulie PG
Cancer Immunol Immunother; 2007 Feb; 56(2):259-69. PubMed ID: 16758204
[TBL] [Abstract][Full Text] [Related]
14. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601.
van der Bruggen P; Szikora JP; Boël P; Wildmann C; Somville M; Sensi M; Boon T
Eur J Immunol; 1994 Sep; 24(9):2134-40. PubMed ID: 7522162
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines.
Zakut R; Topalian SL; Kawakami Y; Mancini M; Eliyahu S; Rosenberg SA
Cancer Res; 1993 Jan; 53(1):5-8. PubMed ID: 8416750
[TBL] [Abstract][Full Text] [Related]
17. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
Corbière V; Nicolay H; Russo V; Stroobant V; Brichard V; Boon T; van der Bruggen P
Tissue Antigens; 2004 May; 63(5):453-7. PubMed ID: 15104676
[TBL] [Abstract][Full Text] [Related]
18. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro.
Dong HL; Sui YF; Li ZS; Qu P; Wu W; Ye J; Zhang XM; Lu SY
Cancer Lett; 2004 Aug; 211(2):219-25. PubMed ID: 15219945
[TBL] [Abstract][Full Text] [Related]
19. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes.
Willemsen RA; Debets R; Hart E; Hoogenboom HR; Bolhuis RL; Chames P
Gene Ther; 2001 Nov; 8(21):1601-8. PubMed ID: 11894998
[TBL] [Abstract][Full Text] [Related]
20. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules.
Luiten RM; Demotte N; Tine J; van der Bruggen P
Tissue Antigens; 2000 Jul; 56(1):77-81. PubMed ID: 10958359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
